ArticleQuantitative imaging in medicine and surgery2025
Prediction of axillary lymph node metastasis in T1 breast cancer using diffuse optical tomography, strain elastography and molecular markers.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A balanced view of imaging and molecular markers for predicting axillary lymph node metastasis in T1 breast cancer.Quantitative imaging in medicine and surgery · 2025Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early-stage breast cancer (BC) presents a certain risk of axillary lymph node (ALN) metastasis (ALNM), leading to different individualized treatment. Preoperative non-invasive prediction to determine ALN status is of great significance for avoiding ineffective axillary surgery. Tumor total hemoglobin concentration (TTHC), strain ratio (SR), and Ki-67 expression are associated with ALNM in BC, but few studies have focused on T1 BC. This study aimed to explore the usefulness of these factors individually and in combination for the preoperative prediction of ALNM in T1 BC. Methods: This was a cross-sectional study. A total of 122 patients with T1 BC were enrolled. TTHC and SR were assessed preoperatively using diffuse optical tomography and strain elastography, respectively. All patients were pathologically evaluated to determine ALN status. Univariate analysis and logistic regression trend test were performed to identify independent predictors. A combined model of imaging-pathological parameters for ALNM was developed. Results: Histopathological analysis indicated that 56 patients (45.9%) exhibited ALNM. The fully adjusted model demonstrated a significant trend correlating increased TTHC (P<0.01 for trend), SR (P<0.001 for trend), and Ki-67 expression (P=0.004 for trend) with ALNM. The area under the receiver operating characteristic curves (AUCs) of TTHC, SR, and Ki-67 expression for predicting ALNM were 0.707 [95% confidence interval (CI): 0.61-0.80], 0.718 (95% CI: 0.63-0.81) and 0.642 (95% CI: 0.56-0.73), respectively. The integration of imaging parameters (TTHC and SR) and Ki-67 expression yielded superior predictive performance for ALN status compared to each parameter individually, as evidenced by an AUC of 0.837 (95% CI: 0.76-0.91). The Hosmer-Lemeshow test P value was 0.880, demonstrating good calibration. In the subgroup analysis, the model exhibited positive predictive capabilities (AUC >0.75) across various subgroups, including molecular subtype, pathological type, and grade. Notably, the predictive performance was particularly enhanced in patients with invasive lobular carcinomas and triple-negative BC, with AUC values exceeding 0.90 for both subgroups. Conclusions: The study found that TTHC ≥185.75 µmol/L, SR ≥3.93 and Ki-67 expression ≥20% were strongly associated with ALNM in patients with T1 BC. The combined imaging-pathological model might provide a convenient preoperative method for predicting ALN status, which can assist clinicians in individualizing management for patients with early-stage BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.